Arbutus Biopharma Corporation ABUS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's stock-based comp?
- Arbutus Biopharma Corporation (ABUS) reported stock-based comp of $1.36M in Q1 2026.
- How has Arbutus Biopharma Corporation's stock-based comp changed year-over-year?
- Arbutus Biopharma Corporation's stock-based comp decreased by 61.9% year-over-year, from $3.56M to $1.36M.
- What is the long-term trend for Arbutus Biopharma Corporation's stock-based comp?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's stock-based comp has grown at a 2.0% compound annual growth rate (CAGR), from $6.42M to $6.95M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.